profit from every $100 of sales.
$0$100
N2OFF
We have no price for N2OFF since 12 June 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$4.80-4.19% today
-85.6% since Oct 8, 25
1-year low $3.711-year high $35.84
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
N2OFF vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| N2OFF | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 22.0× · Fair price | ||
 CSL | 22.1× · Fair price |
AI analysis
An AI analyst reads N2OFF's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisNo annual statements on file yet.
Valuation
- –
- –
- –
- 232.4×
- –
- –
- –
- -76.3%
- -80.2%
- 0.0%
Profitability
- –
- 10,362.1%
- 15,562.1%
- 13,447.0%
- -45.3%
- -80.4%
- -94.1%
- -62.6%
- -46.7%
- -657.6%
Growth
- –
- –
- −11.4%
- –
- +229.9%
Financial health
- 0.4×
- 0.03
- 2.3%
- -5.2×
- 4.73
- 4.73
- -0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 958
Bottom 1%of 987
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -10.74 | – | – |
| Mar 31, 2026 | 4.99 | – | – |
| Nov 13, 2025 | -8.29 | – | – |
| Aug 14, 2025 | -6.29 | – | – |
| May 15, 2025 | -0.39 | – | – |
| Mar 31, 2025 | -0.24 | – | – |
| Nov 14, 2024 | -0.39 | – | – |
| Aug 14, 2024 | -0.23 | – | – |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
39No pass
Benjamin Graham
64Pass
Philip Fisher
45No pass
Peter Lynch
11No pass
Joel Greenblatt
4No pass
Charlie Munger
54No pass
Terry Smith
48No pass
Questions about N2OFF
Is N2OFF a good stock to buy?
A strong, very profitable business that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the N2OFF AI analysis
What does N2OFF do?
N2OFF, Inc., an agri-food technology firm, specializes in creating and distributing sustainable, environmentally conscious treatments for the food sector. It is in Biotechnology.
Does N2OFF pay a dividend?
No. N2OFF does not pay a dividend at the moment.
Is N2OFF stock halal?
Yes. N2OFF passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
Who are N2OFF's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with N2OFF's.
Prices: daily closes to Jun 12, 2026. Fundamentals: company reports via invest-like data.